Ayala Pharmaceuticals inks $30 mln Series B
Wilmington, Delaware and Israel-based Ayala Pharmaceuticals Inc, a clinical-stage company developing medicines for cancers that are genetically defined, has raised $30 million in Series B financing. Novartis led the round with participation from other investors that included SBI JI Innovation Fund, Israel Biotech Fund, aMoon and Harel Insurance & Finance Group.
29 May 2019•1 min read
